Ekta Aggarwal

Principal Account Manager

John Bell

CEO-Founder

Aaron Bell

Director, Google Research

Brendan Bulik-Sullivan

General Partner

Terri Burns

Partner

Brad Calder

VP and GM, Google Cloud Platform and Technical Infrastructure

Sumiran Das

Growth Equity Investor at Google Capital

Jamal Eason

Director of Product Management

Karim Faris

General Partner

Jacquelline Fuller

President

Raj Gajwani

Director, Orion Wifi @ Google Area 120

Margaret Georgiadis

President, Americas

Carletta Higginson

Director, Global Head of Music Publishing

Rahul Jain

Lead, Venture Capital and Startups - Google Cloud

Aftab Jutt

CEO

Sushrut Karanjkar

Director

David Krane

Mnaging Partner

Jess Kuizon

CEO

Skye Lee

Director of UX

Bibiana Leite

Director, Scaled Partnerships

Anthony Nakache

Managing Director, Google MENA

David Reshef

Venture Partner

Issi Rozen

Venture Partner

Philipp Schindler

Senior Vice President and Chief Business Officer

Aparna Sinha

Director, Product Management for Kubernetes and Anthos

Andrew R. Whalley

Director, Chrome Security

Andy Wheeler

General Partner

LightRoom Premium Mod APK Download Android

CEO

Co khi Nhan Do

CEO

Past deals in Medical

Merida Biosciences

Series A in 2025
Merida Biosciences is a biotechnology company specializing in the development of precision therapies for autoimmune diseases. It employs a protein engineering platform to create novel Fc therapeutics, which selectively target and neutralize specific antibodies, aiming to treat the root cause of antibody-driven diseases with high precision and durability.

Layer Health

Series A in 2025
Layer Health is a technology company specializing in AI-driven healthcare information solutions. It develops an AI-powered platform designed to help healthcare providers extract valuable insights from patient data, enabling them to make informed decisions, enhance patient care, and improve overall efficiency. The platform focuses on processing unstructured data from clinical, administrative, and research sources, transforming it into actionable insights to support providers in their clinical and operational tasks.

Perceive Pharma

Series A in 2025
Perceive Pharma operates as a pharmaceutical company. Perceive Pharma develops innovative small molecule neuroprotective treatments.

Allara Health

Series B in 2025
Allara is a healthcare program focused on providing specialized virtual care for women dealing with complex chronic health conditions, particularly polycystic ovary syndrome. The platform connects patients with medical providers and registered dietitians, offering a comprehensive approach that includes diagnostic testing, prescriptions, and personalized video consultations. Allara emphasizes holistic care, integrating dietary and lifestyle changes alongside nutrition counseling to help women manage their health effectively. Through its virtual appointments, the program aims to simplify access to expert care, enabling patients to track and improve their overall medical wellbeing.

Rhygaze

Series A in 2025
Rhygaze is focused on developing a novel gene therapy aimed at restoring vision in patients affected by diseases that lead to blindness. The company's innovative technology specifically targets cone cells, which are crucial for light detection but may lose sensitivity due to various conditions. By delivering a light-sensor gene directly to these compromised cone cells, Rhygaze seeks to repair their ability to detect light, thereby offering potential vision restoration solutions for individuals suffering from blindness.

Leyden Labs

Series B in 2025
Leyden Labs is a biotechnology company focused on developing intranasal products aimed at protecting individuals from respiratory viruses. By targeting commonalities among various viral families, Leyden Labs seeks to provide broad-spectrum protection against multiple strains of viruses, including those in the influenza and coronavirus families. Unlike traditional vaccines that typically address specific variants, Leyden Labs' innovative approach allows for simultaneous protection against a range of viruses, thereby empowering individuals to safeguard their health and prevent the transmission of diseases. The company's team comprises experienced biotechnology professionals and new talent, all committed to advancing solutions that alleviate the impact of respiratory infections on global health.

Synapticure

Series A in 2024
Synapticure is a virtual clinical care platform dedicated to supporting patients with neurodegenerative diseases, including dementia, Parkinson's, and ALS, throughout the United States. Founded by patients, the company offers comprehensive care services that include access to disease-specific neurologists, speech and language therapy, and 24/7 care coordination. Utilizing advances in science, technology, and computational analytics, Synapticure ensures that patients receive tailored treatment and support in their own homes. The platform integrates medical, dental, vision, and life insurance plans to facilitate easy access to a range of healthcare services, including behavioral health support such as psychiatry and therapy, all aimed at enhancing the quality of life for individuals facing these challenging conditions.

Vitara Biomedical

Series B in 2024
Vitara Biomedical is focused on developing a therapeutic platform designed to support premature infants. The company draws inspiration from natural physiological processes to improve neonatal care, aiming to enhance the quality of life for these vulnerable newborns. By addressing the unique challenges faced by premature infants, Vitara Biomedical seeks to reduce mortality rates and associated health complications, ultimately providing a foundation for a healthier future for both infants and their families.

Metsera

Series B in 2024
Metsera is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for obesity and metabolic conditions. The company focuses on advancing a variety of oral and injectable treatment options, including incretin, non-incretin, and combination therapies. These treatments are designed to address multiple therapeutic targets, positioning Metsera to meet the evolving demands of the weight loss treatment landscape. Additionally, Metsera integrates proprietary health technology tools to provide personalized care, enhancing the effectiveness of its therapeutic offerings.

Diverge Health

Series A in 2024
Diverge Health is a healthcare platform designed to support primary care practices in providing quality care to underserved patients. The company enhances these practices by offering a robust infrastructure that includes highly trained community health teams and administrative support. Additionally, Diverge Health integrates technology to facilitate local population health management. This comprehensive approach enables primary care providers to achieve better health outcomes for their patients while successfully navigating the shift towards value-based payment models.

Jacaranda Health

Grant in 2024
Jacaranda Health is a medical services provider in Kenya, specializing in maternal and child health. It operates clinics in underserved, peri-urban areas, offering high-quality, affordable care, including maternity services, general healthcare, and nursing mentorship. Jacaranda's services are designed to be patient-centered and cost a fifth of what private hospitals charge. Notably, the company has achieved a zero maternal mortality rate, significantly lower than Kenya's national average of 400 deaths per 100,000 births. Additionally, Jacaranda Health is involved in research and innovation to improve maternal and newborn health services.

Ubie

Corporate Round in 2024
Ubie, Inc. is a Tokyo-based company founded in 2017 that specializes in developing artificial intelligence-driven healthcare solutions. Its primary product is an AI symptom checker, designed to aid hospitals and physicians by delivering individualized evaluation reports based on patient responses to a brief questionnaire. The system tailors its questions according to various factors, including biological sex, age, medical history, and lifestyle choices. By providing a patient summary and predictive diagnosis, Ubie's technology enhances the diagnostic process, facilitating more personalized care for patients.

Nym

Venture Round in 2024
Nym Health Inc., established in 2017 and headquartered in Boston, Massachusetts, specializes in medical coding technology for healthcare facilities. Its core product, Nym, automates revenue cycle management by interpreting clinical language in patient charts and accurately assigning medical charge codes, reducing operational expenses, improving payment cycles, and enhancing audit readiness. Nym's solution identifies relevant clinical aspects, assigns codes, and provides an audit trail explaining its coding decisions. The company also has a research and development center in Tel Aviv-Yafo, Israel.

PGxAI

Grant in 2024
PGxAI is an AI-powered pharmacogenetics platform that redefines precision medicine using proprietary algorithms and real-world data. Partnered with InterSystems, the largest patient data holder globally, and leveraging advanced tools like VectorSearch and GenAI, PGxAI accesses extensive real-world data to solve drug selection, dosage personalization, and identification of clinically relevant drug-drug interactions.

Cardurion Pharmaceuticals

Series B in 2024
Cardurion Pharmaceuticals, LLC is a biotechnology company based in Boston, Massachusetts, established in 2017. The company specializes in developing innovative therapeutics aimed at treating heart failure and other cardiovascular diseases. Cardurion is advancing clinical programs that focus on inhibiting PDE9 and CaMKII, utilizing its knowledge of cardiovascular signaling pathways to meet significant patient needs in this area.

Santa Ana Bio

Series B in 2024
Santa Ana Bio is a biotechnology company focused on developing precision therapies for autoimmune and inflammatory diseases. By utilizing advanced technologies such as deep cell profiling, single-cell genomics, and multi-omics platforms, the company designs targeted biologics that aim to provide effective and personalized treatment options. Through its innovative approach, Santa Ana Bio seeks to enhance patient outcomes and improve quality of life for those affected by autoimmune conditions.

Benjamin Franklin Institute of Technology

Grant in 2024
If a technical career is what you seek, Benjamin Franklin Institute of Technology (BFIT) provides you with the education you need to pursue your professional goals. For over a century, BFIT has been one of Boston’s top career colleges. The institute has helped students reach their potential through technical education programs in the following types of fields: * Automotive Technology * Computer Technologies * Electronics Engineering Technology * Mechanical Engineering Technology * Medical Electronics Engineering Technology * Ophthalmic Assisting The Academic Success Center at BFIT ensures that students are given the resources and tools they need to excel in their academics and training. Some of the services offered through the center include: academic advising, special accommodations, tutoring, and more. College life at BFIT is filled with exciting experiences. From dorm life and council leadership to community service and intramural sports, the school encourages students to get involved in extracurricular activities. Applicants who are interested in admissions to the school must submit Accuplacer test results, an application, recommendation letters, and official transcripts for review. The school will waive its enrollment fee for any admissions applications submitted online. Merit and need-based financial aid exists in many forms at BFIT for those who qualify and are looking for tuition assistance.

BridgeBio Oncology Therapeutics

Venture Round in 2024
BridgeBio Oncology Therapeutics is a biopharmaceutical company specializing in the development of precision oncology therapeutics. It focuses on targeting RAS-dependent cancers, leveraging a profound understanding of RAS signaling biology to create drugs that selectively inhibit RAS-driven PI3K activation and a wide spectrum of KRAS mutants. The company aims to provide patients with tailored treatments that address both active and inactive cancer-driving states.

Delphia Therapeutics

Series A in 2024
Delphia Therapeutics, headquartered in Boston, USA, is a biotechnology company focused on developing innovative cancer treatments. It operates a laboratory where researchers study cancer-driving pathways to create targeted therapies. The company's approach involves selectively over-activating certain cancer-linked cell signaling pathways, making tumor cells unsustainable and enabling more effective cancer treatment for patients.

Metsera

Series A in 2024
Metsera is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for obesity and metabolic conditions. The company focuses on advancing a variety of oral and injectable treatment options, including incretin, non-incretin, and combination therapies. These treatments are designed to address multiple therapeutic targets, positioning Metsera to meet the evolving demands of the weight loss treatment landscape. Additionally, Metsera integrates proprietary health technology tools to provide personalized care, enhancing the effectiveness of its therapeutic offerings.

Fabric

Series A in 2024
Fabric is a health tech company that enables healthcare providers to deliver faster, higher quality, and more accessible care while reducing costs via consumer-grade patient experiences that automate workflows for staff.

Oula Health

Series B in 2024
Oula Health, Inc. specializes in maternity care services, offering both in-clinic and home-based prenatal care. Founded in 2019 and located in Brooklyn, New York, Oula aims to transform the maternity care experience by integrating obstetrics and midwifery. The company focuses on providing a personalized and evidence-based approach to pregnancy, combining modern medical practices with a compassionate understanding of human needs. Through its innovative maternity center, Oula sets a new standard for pregnancy care that emphasizes both medical expertise and personal connection.

Areteia Therapeutics

Series A in 2024
Areteia Therapeutics is a biotechnology company focused on improving the management of eosinophilic asthma through an innovative oral drug treatment. The company, which emerged from Knopp, aims to provide patients with a novel therapeutic option that inhibits the maturation of eosinophils—cells that can cause airway damage in asthma patients. Its drug candidate has demonstrated promising results in a phase 2 clinical trial, which showed a reduction in blood eosinophil counts, indicating enhanced lung function. This approach seeks to empower patients by offering a potentially effective and accessible treatment for a severe form of asthma, thereby improving their quality of life and disease management.

Accent Therapeutics

Series C in 2024
Accent Therapeutics, Inc. is a biopharmaceutical company based in Lexington, Massachusetts, focused on developing small molecule therapies for oncology through the innovative field of epitranscriptomics. Founded in 2017, the company explores post-transcriptional chemical modifications of RNA, which play a crucial role in regulating proteins essential for cellular growth and differentiation. By precisely targeting RNA-modifying proteins associated with cancer, Accent Therapeutics aims to translate advanced scientific research into effective treatments for patients, ultimately providing new therapeutic options in the fight against cancer.

Granata Bio

Series A in 2024
Granata Bio is a biotechnology company established in 2018 that specializes in identifying and developing therapeutics for fertility patients. The company focuses on creating a comprehensive portfolio of fertility-related treatments and leverages its expertise in commercialization, late-stage clinical trials, and regulatory development. Granata Bio aims to address significant challenges faced by medical professionals in fertility treatment. Recently, the company announced a partnership with IBSA Institut Biochimique to co-develop a novel subcutaneous progesterone solution, further enhancing its commitment to improving fertility care.

Moonwalk Biosciences

Series A in 2024
Moonwalk Biosciences is a genomic medicine startup focused on developing precision epigenetic therapeutics. The company is creating a profiling and engineering technology platform that leverages advanced artificial intelligence to deliver an in-depth understanding of the epigenome in both health and disease. This innovative approach allows healthcare providers to explore new avenues for therapy discovery and facilitates the reprogramming of cells to restore their healthy state. By integrating AI-driven insights, Moonwalk Biosciences aims to transform the landscape of therapeutic development and improve patient outcomes.

Onward Assist

Grant in 2023
Onward Assist operates an advanced cancer prognostics platform aimed at enhancing treatment decisions for oncologists and ultimately improving patient outcomes. The platform employs machine learning and computer vision to provide automated diagnostic tools and treatment decision support specifically designed for histopathologists, radiologists, and oncologists. Its flagship product, PathAssist, integrates an AI layer with automated diagnostics in histopathology, a pathology workflow solution, and a cost-effective slide digitization hardware. By analyzing and predicting the behavior of cancer cells, Onward Assist facilitates deeper insights into tumors and surrounding tissues, thereby ensuring more accurate prognoses and effective treatment protocols.

Endimension Technology

Non Equity Assistance in 2023
Endimension specializes in artificial intelligence solutions for medical image analysis, focusing on the automatic detection of abnormalities and diseases from medical scans. By leveraging advanced AI algorithms, the company aims to enhance the accuracy of diagnostics, thereby reducing the risk of misdiagnosis among patients. Its platform incorporates predictive analytics to facilitate early-stage disease detection, ultimately improving the efficiency of healthcare organizations and optimizing patient turnaround times.

Seismic Therapeutic

Series B in 2023
Seismic Therapeutic is a biotechnology company focused on accelerating immunology drug development through the integration of machine learning in the biologics discovery process. Its IMPACT™ platform addresses key challenges in biologics discovery by combining structural biology, protein engineering, and translational immunology. This innovative approach aims to create optimized therapies more efficiently, ultimately benefiting patients with autoimmune diseases and disorders linked to adaptive immune system dysregulation. With a robust pipeline of biologics, Seismic Therapeutic is committed to enhancing the speed and efficacy of drug development in the field of immunology.

Layer Health

Seed Round in 2023
Layer Health is a technology company specializing in AI-driven healthcare information solutions. It develops an AI-powered platform designed to help healthcare providers extract valuable insights from patient data, enabling them to make informed decisions, enhance patient care, and improve overall efficiency. The platform focuses on processing unstructured data from clinical, administrative, and research sources, transforming it into actionable insights to support providers in their clinical and operational tasks.

Allara Health

Series A in 2023
Allara is a healthcare program focused on providing specialized virtual care for women dealing with complex chronic health conditions, particularly polycystic ovary syndrome. The platform connects patients with medical providers and registered dietitians, offering a comprehensive approach that includes diagnostic testing, prescriptions, and personalized video consultations. Allara emphasizes holistic care, integrating dietary and lifestyle changes alongside nutrition counseling to help women manage their health effectively. Through its virtual appointments, the program aims to simplify access to expert care, enabling patients to track and improve their overall medical wellbeing.

Causal Foundry

Grant in 2023
Causal Foundry is a personalization to solve the greatest challenges in healthcare and medicine.

Jacaranda Health

Grant in 2023
Jacaranda Health is a medical services provider in Kenya, specializing in maternal and child health. It operates clinics in underserved, peri-urban areas, offering high-quality, affordable care, including maternity services, general healthcare, and nursing mentorship. Jacaranda's services are designed to be patient-centered and cost a fifth of what private hospitals charge. Notably, the company has achieved a zero maternal mortality rate, significantly lower than Kenya's national average of 400 deaths per 100,000 births. Additionally, Jacaranda Health is involved in research and innovation to improve maternal and newborn health services.

RAD-AID International

Grant in 2023
RAD-AID International is dedicated to improve radiology services in the developing world and poor areas.

ROME Therapeutics

Series B in 2023
ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Established in 2019, the company utilizes the repeatome—a previously overlooked segment of genetic material—to create novel treatment options. By identifying multiple drug targets and advancing several discovery programs, ROME Therapeutics aims to tap into this unexplored area of biology. The organization has assembled a team of experts in oncology, immunology, virology, and machine learning to lead its research and development efforts, which are designed to provide healthcare professionals with effective new treatments for patients suffering from these conditions.

Nimbus Therapeutics

Private Equity Round in 2023
Nimbus Therapeutics, based in Cambridge, Massachusetts, is a biotechnology company focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. The company utilizes advanced computational technologies to create selective and potent small-molecule therapeutics. Among its notable projects is the Nimbus Apollo program, which features the lead candidate NDI-010976, an allosteric inhibitor targeting Acetyl-CoA Carboxylase (ACC). This compound is being developed for the treatment of non-alcoholic steatohepatitis (NASH) and has potential applications in hepatocellular carcinoma (HCC) and other diseases. NDI-010976 received Fast Track designation from the U.S. Food and Drug Administration in 2016, highlighting its significance in the clinical development pipeline. Nimbus Therapeutics has formed strategic partnerships to enhance its research and development capabilities, reinforcing its commitment to advancing treatment options for complex health challenges.

EpiBiologics

Series A in 2023
EpiBiologics focuses on developing antibody-based targeted therapies aimed at membrane and extracellular proteins that contribute to various diseases. The company utilizes its EpiTAC platform to create therapeutics that degrade these disease-driving proteins, addressing the underlying biology of disorders. By specializing in protein degradation, EpiBiologics enables researchers to manipulate cellular proteostasis, offering potential solutions for a wide range of medical conditions.

Delve Bio

Series A in 2023
Delve Bio is a biotechnology company focused on delivering molecular insights to enhance precision patient care. It specializes in the pathogen-agnostic and unbiased detection of neuro-infectious pathogens in cerebrospinal fluid (CSF). By providing comprehensive diagnostic solutions in a single test, Delve Bio equips laboratories and clinicians with critical information necessary for identifying both common and rare infectious diseases, thereby facilitating more accurate and timely medical interventions.

Bitterroot Bio

Series A in 2023
Bitterroot Bio is a biotechnology company focused on developing innovative immunotherapy-based treatments for cardiovascular disease. By harnessing the immune system's natural capabilities to combat illness, the company conducts research to understand the significant roles of immune cells and immune modulators in the onset and advancement of cardiovascular conditions. Through its commitment to advancing medical treatments, Bitterroot Bio aims to provide effective therapies that can transform cardiovascular disease management and improve patient outcomes.

Antiva Biosciences

Series E in 2023
Antiva Biosciences is a biopharmaceutical company based in South San Francisco, California, focused on developing antiviral drugs to treat human papillomavirus (HPV) infections. Founded in 2012 and previously known as Hera Therapeutics, the company aims to prevent cancer by addressing precancerous lesions associated with HPV. Antiva's innovative approach involves localized therapeutics and small molecule antivirals designed to improve health outcomes for patients suffering from diseases linked to HPV and other viruses. The company's clinical programs target high-grade anal intraepithelial neoplasias and high-grade cervical intraepithelial neoplasias, utilizing a medicinal chemistry platform that emphasizes the development and commercialization of direct-acting antivirals.

Fabric

Seed Round in 2023
Fabric is a health tech company that enables healthcare providers to deliver faster, higher quality, and more accessible care while reducing costs via consumer-grade patient experiences that automate workflows for staff.

EpiBiologics

Series A in 2023
EpiBiologics focuses on developing antibody-based targeted therapies aimed at membrane and extracellular proteins that contribute to various diseases. The company utilizes its EpiTAC platform to create therapeutics that degrade these disease-driving proteins, addressing the underlying biology of disorders. By specializing in protein degradation, EpiBiologics enables researchers to manipulate cellular proteostasis, offering potential solutions for a wide range of medical conditions.

Chroma Medicine

Series B in 2023
Chroma Medicine is a genomic medicine company founded in 2021 and based in Cambridge, Massachusetts, specializing in epigenetic editing. The company is pioneering a new class of genomic therapies aimed at revolutionizing the treatment of genetically driven diseases. By utilizing epigenetics, which is the natural mechanism for gene regulation, Chroma Medicine develops programmable epigenetic editors that target specific genes and modulate chromatin conformation. This innovative approach enables healthcare providers to achieve precise control of gene expression, offering a promising therapeutic option for conditions linked to genetic anomalies.

Santa Ana Bio

Series A in 2023
Santa Ana Bio is a biotechnology company focused on developing precision therapies for autoimmune and inflammatory diseases. By utilizing advanced technologies such as deep cell profiling, single-cell genomics, and multi-omics platforms, the company designs targeted biologics that aim to provide effective and personalized treatment options. Through its innovative approach, Santa Ana Bio seeks to enhance patient outcomes and improve quality of life for those affected by autoimmune conditions.

Aera Therapeutics

Series B in 2023
Aera Therapeutics is a biotechnology company focused on enhancing the delivery of genetic medicines through its proprietary protein nanoparticle (PNP) platform. This innovative platform utilizes endogenous human proteins to create capsid-like structures that can effectively package and transfer nucleic acid cargo. By addressing the limitations of current delivery technologies, Aera aims to extend the application of genetic medicines across various tissues and disease areas, ultimately benefiting a wider patient population. In addition to its PNP platform, Aera has developed a therapeutic enzyme platform that features novel, compact, and programmable gene-editing enzymes, further advancing its mission to transform the field of genetic medicine.

Aera Therapeutics

Series A in 2023
Aera Therapeutics is a biotechnology company focused on enhancing the delivery of genetic medicines through its proprietary protein nanoparticle (PNP) platform. This innovative platform utilizes endogenous human proteins to create capsid-like structures that can effectively package and transfer nucleic acid cargo. By addressing the limitations of current delivery technologies, Aera aims to extend the application of genetic medicines across various tissues and disease areas, ultimately benefiting a wider patient population. In addition to its PNP platform, Aera has developed a therapeutic enzyme platform that features novel, compact, and programmable gene-editing enzymes, further advancing its mission to transform the field of genetic medicine.

Paradigm

Series A in 2023
Paradigm is rebuilding the clinical research ecosystem by developing a platform that allows all patients equitable access to trials while improving trial efficiency and lowering barriers to participation for healthcare providers. It is an innovative company that is dedicated to transforming the clinical research ecosystem. Their mission is to create a more accessible and equitable healthcare system by developing a platform that enables patients from diverse backgrounds to participate in clinical trials. Clinical trials are essential for testing and developing new drugs, therapies, and medical devices, but historically, they have been plagued by inefficiencies, barriers to access, and inequities in patient representation. Paradigm aims to solve these challenges by creating a platform that uses technology and data-driven insights to streamline the clinical trial process, making it more efficient, cost-effective, and inclusive. The Paradigm platform is designed to facilitate seamless communication and collaboration among all stakeholders involved in clinical research, including patients, healthcare providers, pharmaceutical companies, and regulatory agencies. By leveraging technology such as AI, machine learning, and predictive analytics, Paradigm can identify and match eligible patients to clinical trials, streamline the recruitment and enrollment process, and provide real-time data insights to all stakeholders. Overall, Paradigm's innovative approach to clinical research has the potential to revolutionize the healthcare industry by improving patient outcomes, reducing healthcare costs, and accelerating the development of new treatments and therapies.

Britto's Brainwaves

Seed Round in 2023
Britto's Brainwaves is a healthcare company that emerges as a beacon for those seeking in-depth medical insights.

FogPharma

Series D in 2022
FogPharma is a biotechnology company focused on developing innovative cancer therapies through its unique cell-penetrating mini proteins (CPMPs). Founded by Greg Verdine, the company aims to address cancer-causing proteins that are typically inaccessible to traditional treatments. By collaborating with leading experts in cancer biology and therapy, FogPharma is creating a new class of medicines designed to neutralize these challenging targets. The company is supported by a diverse group of private and institutional investors, which enables it to pursue its mission of delivering transformative cancer treatments. FogPharma is dedicated to improving the lives of patients and their families, striving to extend both life expectancy and quality of life.

Vitara Biomedical

Series B in 2022
Vitara Biomedical is focused on developing a therapeutic platform designed to support premature infants. The company draws inspiration from natural physiological processes to improve neonatal care, aiming to enhance the quality of life for these vulnerable newborns. By addressing the unique challenges faced by premature infants, Vitara Biomedical seeks to reduce mortality rates and associated health complications, ultimately providing a foundation for a healthier future for both infants and their families.

Kindbody

Venture Round in 2022
Kindbody is a comprehensive fertility clinic network and family-building benefits provider that offers a wide range of services aimed at improving access to healthcare for women. The company provides both virtual and in-person care, including fertility assessments, education, preservation, genetic testing, in vitro fertilization (IVF), donor and surrogacy services, and adoption. By partnering with employers, Kindbody delivers financial, medical, and emotional support to employees pursuing parenthood. The company serves more than 100 employers, covering over 2.4 million lives, while also providing direct fertility care through its network of signature clinics, mobile clinics, and partner clinics across the country. With a focus on affordability and accessibility, Kindbody employs modern technology to deliver holistic health and fertility services.

Xilis

Series A in 2022
Xilis, Inc. is a biotechnology company based in Chapel Hill, North Carolina, founded in 2019. It specializes in developing advanced organoid technologies aimed at guiding precision therapy for cancer patients and enhancing drug discovery processes. The company's flagship platform, XilisµO, facilitates rapid diagnostics and personalized drug screening while providing scalable, patient-derived models for high-throughput drug discovery. This technology supports physicians and pharmaceutical companies in creating tailored treatments by enabling effective drug screening, ultimately contributing to more precise and cost-efficient cancer therapies.

Areteia Therapeutics

Series A in 2022
Areteia Therapeutics is a biotechnology company focused on improving the management of eosinophilic asthma through an innovative oral drug treatment. The company, which emerged from Knopp, aims to provide patients with a novel therapeutic option that inhibits the maturation of eosinophils—cells that can cause airway damage in asthma patients. Its drug candidate has demonstrated promising results in a phase 2 clinical trial, which showed a reduction in blood eosinophil counts, indicating enhanced lung function. This approach seeks to empower patients by offering a potentially effective and accessible treatment for a severe form of asthma, thereby improving their quality of life and disease management.

Syrona Health

Seed Round in 2022
Syrona Health is a digital health company focused on personalized gynecological care throughout various life stages, including menstrual health and menopause. The platform offers a virtual health support system combined with at-home clinical tests aimed at enhancing gynecological health outcomes. It addresses key women's health issues such as endometriosis, polycystic ovary syndrome (PCOS), fertility, parenthood, and menopause. By leveraging both software and hardware, Syrona Health enables women to monitor their health and receive online counseling, facilitating proactive management of their gynecological conditions without the need for lengthy diagnostic processes in clinics.

Aspen Neuroscience

Series B in 2022
Aspen Neuroscience, Inc. is a biotechnology company focused on developing induced pluripotent stem cells (iPSCs) to create patient-specific therapies for neurological conditions, particularly Parkinson's disease. Founded in 2018 and based in San Diego, California, the company is advancing its pipeline of products, which includes ANPD001, an autologous neuron replacement therapy for sporadic Parkinson's disease, and ANPD002, a gene-edited autologous neuron replacement therapy targeting familial forms of the disease. Aspen Neuroscience employs innovative genomic approaches in conjunction with stem cell biology to address diseases with significant unmet medical needs, aiming to provide restorative cell therapies that can modify the progression of Parkinson's disease and potentially extend to other affected organs.

Viz

Series D in 2022
Viz.ai, Inc. specializes in healthcare imaging software designed to enhance stroke care through the use of artificial intelligence. The company's flagship technology synchronizes treatment by reducing delays in patient care, enabling rapid identification of large vessel occlusion (LVO) strokes using advanced deep learning algorithms. Key offerings include Viz LVO, which alerts on-call stroke teams based on CT angiogram images, and Viz CTP, which analyzes CT perfusion images and generates critical parametric data. Additionally, Viz HUB facilitates communication among clinical teams to coordinate care efficiently, while Viz VIEW allows healthcare professionals to view imaging data on mobile devices. Founded in 2016 and headquartered in San Francisco, the company aims to transform healthcare delivery by improving the speed and accessibility of treatment for stroke patients.

Celsius Therapeutics

Series B in 2022
Celsius Therapeutics is a biotechnology company focused on developing precision medicines for patients with cancer and autoimmune diseases. Founded in 2018 and based in Cambridge, Massachusetts, the company employs a team of scientists, technologists, computational biologists, clinicians, and drug hunters. Utilizing single-cell genomic analysis and machine learning techniques, Celsius Therapeutics aims to discover and create innovative therapies that can lead to significant improvements in patient outcomes. The company's research efforts are centered on identifying new drug candidates that address unmet medical needs in the therapeutic landscape.

LifeMine Therapeutics

Series C in 2022
LifeMine Therapeutics, Inc. is a biotechnology company focused on discovering new drug modalities from eukaryotic microbes, particularly fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, the company employs an integrated platform that combines genomics, artificial intelligence, and synthetic biology. This innovative Avatar-Rx platform utilizes high-throughput microbiology, data science, machine learning, genome engineering, and automation to explore the fungal biosphere for novel genetically encoded molecules with specific biological functions. By integrating chemoinformatic-assisted drug optimization and advanced chemical synthesis with biotransformation, LifeMine Therapeutics aims to advance a pipeline of new medicines into development.

Spotlight Therapeutics

Series B in 2022
Spotlight Therapeutics, Inc. specializes in the development of gene editing therapeutics designed to target specific cell populations directly within the body. Established in 2017 and based in Hayward, California, the company leverages a biotechnology platform that utilizes CRISPR nuclease effectors for in vivo gene editing. Its innovative approach aims to create next-generation programmable nucleases that enhance treatment options for a variety of conditions. Spotlight Therapeutics is focused on multiple therapeutic areas, including immuno-oncology, ophthalmology, and hematology, and is developing programs to address previously undruggable intracellular gene targets as well as specific monogenic disease targets related to the eye. This targeted gene editing strategy seeks to overcome the challenges associated with traditional delivery methods, thereby providing healthcare providers with improved tools for patient treatment.

DNAnexus

Series H in 2022
DNAnexus, Inc. is a provider of cloud-based genome informatics and data management tools aimed at enterprises engaged in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and integration with clinical and phenotypic data, promoting seamless collaboration among users. Key offerings include MOSAIC Microbiome, a platform for collaborative microbiome research; DNAnexus Apollo, which focuses on clinico-genomic data exploration; and DNAnexus Titan, a comprehensive data analysis solution. Additionally, DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration. The Clinico-Genomic Data Solution program addresses the need for disease-specific datasets by building networks with healthcare partners to enhance diagnosis and treatment pathways. DNAnexus serves a diverse client base, including biopharmaceutical companies, genome centers, and diagnostic test providers, and has established a strategic alliance with WuXi NextCODE Genomics. The company also maintains additional offices in San Francisco, London, and Prague.

Seismic Therapeutic

Series A in 2022
Seismic Therapeutic is a biotechnology company focused on accelerating immunology drug development through the integration of machine learning in the biologics discovery process. Its IMPACT™ platform addresses key challenges in biologics discovery by combining structural biology, protein engineering, and translational immunology. This innovative approach aims to create optimized therapies more efficiently, ultimately benefiting patients with autoimmune diseases and disorders linked to adaptive immune system dysregulation. With a robust pipeline of biologics, Seismic Therapeutic is committed to enhancing the speed and efficacy of drug development in the field of immunology.

Synapticure

Seed Round in 2022
Synapticure is a virtual clinical care platform dedicated to supporting patients with neurodegenerative diseases, including dementia, Parkinson's, and ALS, throughout the United States. Founded by patients, the company offers comprehensive care services that include access to disease-specific neurologists, speech and language therapy, and 24/7 care coordination. Utilizing advances in science, technology, and computational analytics, Synapticure ensures that patients receive tailored treatment and support in their own homes. The platform integrates medical, dental, vision, and life insurance plans to facilitate easy access to a range of healthcare services, including behavioral health support such as psychiatry and therapy, all aimed at enhancing the quality of life for individuals facing these challenging conditions.

Leyden Labs

Series B in 2022
Leyden Labs is a biotechnology company focused on developing intranasal products aimed at protecting individuals from respiratory viruses. By targeting commonalities among various viral families, Leyden Labs seeks to provide broad-spectrum protection against multiple strains of viruses, including those in the influenza and coronavirus families. Unlike traditional vaccines that typically address specific variants, Leyden Labs' innovative approach allows for simultaneous protection against a range of viruses, thereby empowering individuals to safeguard their health and prevent the transmission of diseases. The company's team comprises experienced biotechnology professionals and new talent, all committed to advancing solutions that alleviate the impact of respiratory infections on global health.

Verana Health

Series E in 2022
Verana Health, Inc. is a digital health company based in San Francisco, California, that specializes in transforming healthcare data into actionable insights. Founded in 2008 and formerly known as Digisight Technologies, the company connects healthcare providers with patients through innovative solutions. Its flagship product, SightBook, is a mobile application that enables users to test their vision and share results with their physicians in real-time, facilitating timely appointments and treatments. Verana Health manages data from over 20,000 healthcare providers and 70 electronic health record systems, leveraging its AI-enhanced platform, VeraQ™, to create a robust healthcare data ecosystem. By utilizing advanced analytics on curated datasets, Verana Health supports life sciences partners in improving clinical research and enhancing patient care outcomes.

Ankyra

Series B in 2021
Ankyra is a biotechnology company focused on developing anchored immunotherapy for cancer treatment. The company addresses the limitations of traditional cytokine therapies, which are often restricted due to widespread immune activation and associated toxicity. Ankyra's innovative approach involves the use of its Anchored Immunotherapy Platform to create ANK-101, a stable complex of a modified IL-12 cytokine and aluminum hydroxide, an FDA-approved adjuvant. This combination allows for targeted intratumoral delivery, enhancing the localized retention and activity of IL-12 while reducing systemic side effects. By optimizing the therapeutic potential of anchored immunotherapy, Ankyra aims to improve treatment outcomes for cancer patients, offering a safer and more effective alternative to conventional therapies.

Antiva Biosciences

Series D in 2021
Antiva Biosciences is a biopharmaceutical company based in South San Francisco, California, focused on developing antiviral drugs to treat human papillomavirus (HPV) infections. Founded in 2012 and previously known as Hera Therapeutics, the company aims to prevent cancer by addressing precancerous lesions associated with HPV. Antiva's innovative approach involves localized therapeutics and small molecule antivirals designed to improve health outcomes for patients suffering from diseases linked to HPV and other viruses. The company's clinical programs target high-grade anal intraepithelial neoplasias and high-grade cervical intraepithelial neoplasias, utilizing a medicinal chemistry platform that emphasizes the development and commercialization of direct-acting antivirals.

ROME Therapeutics

Series B in 2021
ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Established in 2019, the company utilizes the repeatome—a previously overlooked segment of genetic material—to create novel treatment options. By identifying multiple drug targets and advancing several discovery programs, ROME Therapeutics aims to tap into this unexplored area of biology. The organization has assembled a team of experts in oncology, immunology, virology, and machine learning to lead its research and development efforts, which are designed to provide healthcare professionals with effective new treatments for patients suffering from these conditions.

Genome Medical

Series C in 2021
Genome Medical, Inc. is a genomic medicine delivery company based in South San Francisco, California, established in 2016. It operates a technology platform known as Genome Care Delivery, which connects individuals and healthcare providers with genetic specialists to facilitate virtual genetic consultations. The company focuses on various areas of clinical care, including cancer, cardiovascular health, reproductive health, pediatrics, and pharmacogenomics. By providing expert genetic assessments and personalized clinical action plans, Genome Medical helps patients understand their genetic risks and make informed treatment decisions. Additionally, the company supports healthcare providers in navigating the growing field of genetics, enhancing disease diagnosis, and improving patient care while aiming to reduce overall healthcare costs.

Ultromics

Series B in 2021
Ultromics Limited, founded in 2017 and based in Oxford, United Kingdom, specializes in developing advanced echocardiography software aimed at enhancing the diagnosis of coronary heart disease. The company leverages artificial intelligence to create diagnostic tools that significantly improve the accuracy of echocardiography, with reported enhancements exceeding 90%. Ultromics' technology focuses on analyzing complex data from electrocardiograms, enabling healthcare providers to make informed decisions in diagnosing coronary artery disease. By providing innovative solutions for cardiologists, Ultromics aims to transform cardiovascular diagnostics and improve patient outcomes.

Sonoma Biotherapeutics

Series B in 2021
Sonoma Biotherapeutics develops adoptive Treg cell therapies aimed at treating autoimmune and degenerative diseases. The company employs advanced genome editing and target-specific cell therapy to create therapeutic solutions that promote self-tolerance and mitigate harmful inflammatory responses associated with conditions such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease. Founded in 2019 and headquartered in South San Francisco, California, with an additional office in Seattle, Washington, Sonoma Biotherapeutics combines expertise in Treg biology and proprietary methodologies to advance its therapeutic platform, focusing on developing disease-modifying and potentially curative treatments.

Neuralink

Series C in 2021
Neuralink is focused on developing implantable brain-machine interfaces aimed at assisting individuals with paralysis and addressing neurological conditions. The company is dedicated to creating high-bandwidth devices that not only facilitate treatment and diagnosis but also have the potential to enhance cognitive abilities. By innovating in this field, Neuralink seeks to enable medical professionals to effectively manage serious brain diseases while expanding the capabilities of individuals within the community.

Nym

Venture Round in 2021
Nym Health Inc., established in 2017 and headquartered in Boston, Massachusetts, specializes in medical coding technology for healthcare facilities. Its core product, Nym, automates revenue cycle management by interpreting clinical language in patient charts and accurately assigning medical charge codes, reducing operational expenses, improving payment cycles, and enhancing audit readiness. Nym's solution identifies relevant clinical aspects, assigns codes, and provides an audit trail explaining its coding decisions. The company also has a research and development center in Tel Aviv-Yafo, Israel.

Prime Medicine

Series B in 2021
Prime Medicine is a biotechnology company focused on developing genetic therapies using its proprietary Prime Editing technology. This next-generation gene editing method allows for precise "search and replace" modifications in the genome, aiming to restore normal genetic function and address the underlying causes of various diseases. By targeting a broad spectrum of conditions with significant unmet medical needs, Prime Medicine seeks to revolutionize the field of genetic medicine through effective and efficient therapeutic solutions.

Xilis

Series A in 2021
Xilis, Inc. is a biotechnology company based in Chapel Hill, North Carolina, founded in 2019. It specializes in developing advanced organoid technologies aimed at guiding precision therapy for cancer patients and enhancing drug discovery processes. The company's flagship platform, XilisµO, facilitates rapid diagnostics and personalized drug screening while providing scalable, patient-derived models for high-throughput drug discovery. This technology supports physicians and pharmaceutical companies in creating tailored treatments by enabling effective drug screening, ultimately contributing to more precise and cost-efficient cancer therapies.

Kindbody

Series C in 2021
Kindbody is a comprehensive fertility clinic network and family-building benefits provider that offers a wide range of services aimed at improving access to healthcare for women. The company provides both virtual and in-person care, including fertility assessments, education, preservation, genetic testing, in vitro fertilization (IVF), donor and surrogacy services, and adoption. By partnering with employers, Kindbody delivers financial, medical, and emotional support to employees pursuing parenthood. The company serves more than 100 employers, covering over 2.4 million lives, while also providing direct fertility care through its network of signature clinics, mobile clinics, and partner clinics across the country. With a focus on affordability and accessibility, Kindbody employs modern technology to deliver holistic health and fertility services.

Dyno Therapeutics

Series A in 2021
Dyno Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative adeno-associated virus (AAV) vectors for gene therapy applications. Founded in 2018, the company employs an artificial intelligence-powered platform that integrates next-generation DNA synthesis, high-throughput sequencing, and machine learning. This advanced approach allows Dyno Therapeutics to design and optimize cell-targeting capsids, which are crucial for the effective and safe delivery of gene therapies. By leveraging its technology, the company aims to provide medical researchers with novel AAV vectors that enhance the efficacy of in vivo therapeutic solutions.

Affinia Therapeutics

Series B in 2021
Affinia Therapeutics Inc. is focused on developing gene therapies for various diseases, particularly those affecting the muscles and central nervous system. The company specializes in creating adeno-associated virus (AAV) vectors, leveraging advanced techniques in synthetic and systems biology, as well as high-throughput screening and tissue and single-cell resolution. Founded in 2019 and based in Waltham, Massachusetts, Affinia aims to address significant unmet medical needs by providing rationally designed gene therapies with improved properties. The company's innovative approach seeks to offer effective treatments for devastating conditions that currently lack adequate therapeutic options.

Invivyd

Series C in 2021
Invivyd is a biopharmaceutical company committed to developing antibody-based therapies aimed at providing protection against serious viral infectious diseases. The company focuses on creating solutions that go beyond naturally occurring immunity, particularly in response to viral threats with pandemic potential, starting with SARS-CoV-2. Its product pipeline includes ADG20, which is designed for the treatment and prevention of COVID-19, and VYD222, a monoclonal antibody engineered for enhanced potency and broad coverage. By prioritizing rapid and enduring therapeutic options, Invivyd aims to safeguard vulnerable populations from the severe impacts of circulating viral infections.

Leyden Labs

Series A in 2021
Leyden Labs is a biotechnology company focused on developing intranasal products aimed at protecting individuals from respiratory viruses. By targeting commonalities among various viral families, Leyden Labs seeks to provide broad-spectrum protection against multiple strains of viruses, including those in the influenza and coronavirus families. Unlike traditional vaccines that typically address specific variants, Leyden Labs' innovative approach allows for simultaneous protection against a range of viruses, thereby empowering individuals to safeguard their health and prevent the transmission of diseases. The company's team comprises experienced biotechnology professionals and new talent, all committed to advancing solutions that alleviate the impact of respiratory infections on global health.

Tenaya Therapeutics

Series C in 2021
Tenaya Therapeutics is a biotechnology company based in South San Francisco, California, focused on developing innovative therapies for heart disease, particularly heart failure. Established in 2016, the company employs three main platforms to address the underlying causes of heart disease: a cellular regeneration platform that reprograms cardiac fibroblasts into cardiomyocytes using proprietary transcription factors, a gene therapy platform for targeted delivery of therapeutic payloads, and a precision medicine approach tailored to individual patients. Through these platforms, Tenaya Therapeutics aims to enable the regeneration of heart tissue and tackle various forms of cardiomyopathies, leveraging advanced research in cardiac development and regeneration.

Hyperfine

Series D in 2021
Hyperfine is a medical device company that developed Swoop, the first FDA-cleared point-of-care MRI system designed to enhance patient access to diagnostic imaging. Swoop operates at a lower magnetic field strength than traditional MRI machines, producing high-quality images quickly and efficiently. This portable system can be easily wheeled to a patient's bedside, plugged into a standard electrical outlet, and operated via an iPad, making it suitable for various clinical environments such as emergency departments and intensive care units. Hyperfine generates revenue through the sale of MRI devices and service sales, which include subscriptions for bundled devices, maintenance, and software. By providing rapid imaging capabilities at a fraction of the cost of conventional MRIs, Hyperfine aims to facilitate timely diagnoses and treatments for patients, regardless of their location or resources.

SpyBiotech

Series A in 2021
SpyBiotech Limited, founded in 2017 and based in Oxford, United Kingdom, specializes in the development of innovative vaccines using a proprietary technology known as molecular superglue. This platform allows for the rapid creation of bonding vaccines by attaching antigens to viruses and other particles, enhancing the vaccine development process. By leveraging this unique approach, SpyBiotech aims to provide medical institutions and research centers with more effective vaccines that can be developed in a shorter timeframe, ultimately improving immunity against various diseases, including bacterial infections.

TScan Therapeutics

Series C in 2021
TScan Therapeutics is a biopharmaceutical company dedicated to discovering and developing innovative T cell receptor (TCR) engineered therapies to combat various cancers. Based in Waltham, Massachusetts, the company focuses on TCR-T therapies for both liquid cancers and solid tumors. Its lead candidates, TSC-100 and TSC-101, are designed to address hematologic malignancies, specifically targeting residual leukemia and preventing relapse after hematopoietic stem cell transplantation. In addition, TScan is advancing a multiplexed TCR-T therapy program aimed at treating a range of solid tumors. The company's proprietary platform identifies clinically relevant T cell antigens and minimizes off-target effects, enhancing the precision of its therapies. Founded in 2018, TScan Therapeutics is committed to improving outcomes for patients with serious diseases.

Vera Therapeutics

Series C in 2021
Vera Therapeutics, a biotechnology company based in South San Francisco, California, specializes in developing innovative biologic therapeutics aimed at treating serious immunological diseases and genetic disorders. Founded in 2016 and renamed in March 2020, the company's research focuses on transformative treatments that can significantly improve patient outcomes. One of its key product candidates is atacicept, a fusion protein designed for self-administration via a weekly subcutaneous injection. Atacicept works by inhibiting both B lymphocyte stimulator and a proliferation-inducing ligand, which are involved in the production of autoantibodies that contribute to various autoimmune diseases. Additionally, Vera Therapeutics is exploring gene-editing technologies that hold the potential to address conditions such as sickle cell disease and cystic fibrosis.

Verve Therapeutics

Series B in 2021
Verve Therapeutics, Inc. is a genetic medicines company focused on innovative treatments for cardiovascular disease through gene editing. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company aims to shift the management of cardiovascular conditions from chronic treatments to single-course gene editing therapies. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are known to significantly impact blood lipid levels, a major factor in cardiovascular disease. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance its gene editing delivery technologies. The company is staffed by a team of experts in cardiovascular medicine, human genetics, and drug development, positioning itself to address the challenges of cardiovascular health effectively.

EQRx

Series B in 2021
EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on transforming the drug discovery and delivery process to address the rising costs of medicines. Founded in 2019, EQRx aims to provide a market-based solution by leveraging advances in science and technology while collaborating with various healthcare stakeholders. The company has over ten programs in its pipeline targeting oncology and immune-inflammatory conditions, which include clinical and preclinical stages, as well as drug engineering initiatives. Among its key programs are Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab. Through its innovative approach, EQRx seeks to develop high-quality, patent-protected medicines more efficiently and cost-effectively than traditional pharmaceutical methods.

LifeMine Therapeutics

Series B in 2021
LifeMine Therapeutics, Inc. is a biotechnology company focused on discovering new drug modalities from eukaryotic microbes, particularly fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, the company employs an integrated platform that combines genomics, artificial intelligence, and synthetic biology. This innovative Avatar-Rx platform utilizes high-throughput microbiology, data science, machine learning, genome engineering, and automation to explore the fungal biosphere for novel genetically encoded molecules with specific biological functions. By integrating chemoinformatic-assisted drug optimization and advanced chemical synthesis with biotransformation, LifeMine Therapeutics aims to advance a pipeline of new medicines into development.

IconOVir Bio

Series A in 2021
IconOVir Bio is a preclinical-stage biotechnology company focused on developing innovative oncolytic virus therapies for cancer treatment. The company's proprietary platform aims to overcome the limitations associated with first- and second-generation oncolytic viruses, thereby enhancing the therapeutic options available to healthcare professionals. By prioritizing personalized therapy, IconOVir Bio seeks to improve treatment outcomes for cancer patients, positioning itself at the forefront of advancements in oncology.

FogPharma

Venture Round in 2021
FogPharma is a biotechnology company focused on developing innovative cancer therapies through its unique cell-penetrating mini proteins (CPMPs). Founded by Greg Verdine, the company aims to address cancer-causing proteins that are typically inaccessible to traditional treatments. By collaborating with leading experts in cancer biology and therapy, FogPharma is creating a new class of medicines designed to neutralize these challenging targets. The company is supported by a diverse group of private and institutional investors, which enables it to pursue its mission of delivering transformative cancer treatments. FogPharma is dedicated to improving the lives of patients and their families, striving to extend both life expectancy and quality of life.

Encodia

Series C in 2020
Encodia, Inc., founded in 2015 and headquartered in San Diego, California, specializes in proteomics research and the development of innovative protein analysis technology. The company offers a platform that utilizes reverse-translation technology to convert peptide sequence information into DNA libraries, facilitating scalable and efficient protein sequencing. This capability enables researchers to analyze protein samples comprehensively, thereby advancing the field of personalized medicine. By democratizing access to detailed information on cellular processes, Encodia aims to accelerate the discovery of novel approaches to addressing challenging diseases.

Locanabio

Series B in 2020
Locanabio, Inc. is a biotechnology company based in San Diego, California, founded in 2016. It specializes in developing RNA-targeted gene therapies aimed at treating a range of underserved diseases, particularly in the areas of neuromuscular, neurodegenerative, and retinal conditions. The company's innovative platform focuses on modifying disease-causing RNA, allowing for the identification and correction of specific RNA sequences associated with rare genetic disorders. This approach distinguishes Locanabio's therapies from traditional DNA-targeted methods, offering a unique solution for patients with severe and challenging health issues. The company, which rebranded from Locana, Inc. in July 2020, is dedicated to advancing therapeutic candidates that address significant medical needs.

Olive

Venture Round in 2020
Olive deploys the AI workforce built specifically for healthcare, delivering hospitals and health systems increased revenue, reduced costs, and increased capacity. Olive automates repetitive, high-volume tasks and workflows, monitoring their performance, identifying improvements, and finding opportunities for new work. Olive gives power back to providers through her ever-growing, unparalleled intelligence made up of shared memories, collective wisdom, and global awareness, learning like a network so hospitals never have to solve the same problem twice. Olive was founded in 2012 and is headquartered in Columbus, Ohio.

Spotlight Therapeutics

Series A in 2020
Spotlight Therapeutics, Inc. specializes in the development of gene editing therapeutics designed to target specific cell populations directly within the body. Established in 2017 and based in Hayward, California, the company leverages a biotechnology platform that utilizes CRISPR nuclease effectors for in vivo gene editing. Its innovative approach aims to create next-generation programmable nucleases that enhance treatment options for a variety of conditions. Spotlight Therapeutics is focused on multiple therapeutic areas, including immuno-oncology, ophthalmology, and hematology, and is developing programs to address previously undruggable intracellular gene targets as well as specific monogenic disease targets related to the eye. This targeted gene editing strategy seeks to overcome the challenges associated with traditional delivery methods, thereby providing healthcare providers with improved tools for patient treatment.

Invivyd

Series B in 2020
Invivyd is a biopharmaceutical company committed to developing antibody-based therapies aimed at providing protection against serious viral infectious diseases. The company focuses on creating solutions that go beyond naturally occurring immunity, particularly in response to viral threats with pandemic potential, starting with SARS-CoV-2. Its product pipeline includes ADG20, which is designed for the treatment and prevention of COVID-19, and VYD222, a monoclonal antibody engineered for enhanced potency and broad coverage. By prioritizing rapid and enduring therapeutic options, Invivyd aims to safeguard vulnerable populations from the severe impacts of circulating viral infections.

Decibel Therapeutics

Series D in 2020
Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing therapies aimed at protecting, repairing, and restoring hearing. The company focuses on a range of hearing disorders, including those related to cancer treatments, cystic fibrosis, noise exposure, age-related and genetic hearing loss, as well as tinnitus. It utilizes advanced techniques such as single-cell genomics, bioinformatics, and precision gene therapy technologies to enhance its understanding of inner ear pathology and to develop effective treatments. Decibel Therapeutics also offers expertise in drug delivery to the inner ear, imaging, and pharmacokinetic modeling, contributing to innovative therapeutic approaches for patients experiencing various forms of hearing loss. Founded in 2013 and based in Boston, Massachusetts, Decibel Therapeutics was previously known as Hearing, Inc. before rebranding in 2014.

Nym

Series A in 2020
Nym Health Inc., established in 2017 and headquartered in Boston, Massachusetts, specializes in medical coding technology for healthcare facilities. Its core product, Nym, automates revenue cycle management by interpreting clinical language in patient charts and accurately assigning medical charge codes, reducing operational expenses, improving payment cycles, and enhancing audit readiness. Nym's solution identifies relevant clinical aspects, assigns codes, and provides an audit trail explaining its coding decisions. The company also has a research and development center in Tel Aviv-Yafo, Israel.

Ready

Series C in 2020
Ready Responders, Inc. focuses on enhancing community health by providing immediate medical care and support for various health needs. Founded in 2016 and headquartered in New Orleans, Louisiana, the company offers services such as 911 quick responses, telehealth consultations, and patient access to emergency medical professionals. Their responders visit patients at home to address physical, mental, and social health needs, utilizing technology to connect with advanced medical providers. Ready Responders also facilitates connections to external resources for ongoing support and aims to improve patient experiences while reducing overall care costs. The company operates in multiple locations across Louisiana, Nevada, New York City, and the National Capital Region, and is in-network with many major insurance providers.

Arkangel AI

Grant in 2020
Arkangel AI is a healthcare-focused technology company that provides a no-code artificial intelligence platform designed to help organizations develop, deploy, and manage machine learning algorithms at scale. Its platform enables the efficient detection of preventable diseases, producing results that are faster, scalable, accurate, and cost-effective. By facilitating the identification of health issues and their stages, Arkangel AI aims to promote equitable health conditions globally, empowering users to lead healthier lives free from preventable diseases.

Kronos Bio

Private Equity Round in 2020
Kronos Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative cancer therapeutics. Founded in 2017 and headquartered in San Mateo, California, the company focuses on targeting dysregulated transcription factors and oncogenic signaling pathways. Its lead candidate, entospletinib, is a selective inhibitor of spleen tyrosine kinase aimed at treating acute myeloid leukemia. Additionally, Kronos Bio is developing KB-0742, an orally bioavailable inhibitor of cyclin-dependent kinase 9, intended for MYC-amplified solid tumors. By leveraging advanced technologies such as high-throughput small-molecule microarrays and targeted protein degradation, Kronos Bio aims to identify effective compounds that can modulate historically undruggable cancer targets, ultimately striving to improve patient outcomes through precision medicine.

Taysha Gene Therapies

Series B in 2020
Taysha Gene Therapies, Inc. is a gene therapy company based in Dallas, Texas, established in 2019, focused on developing adeno-associated virus (AAV)-based gene therapies for monogenic diseases affecting the central nervous system (CNS). The company’s product pipeline includes several therapies currently in development, such as TSHA-101 for GM2 gangliosidosis, TSHA-118 for CLN1 disease, TSHA-102 for Rett syndrome, TSHA-103 for SLC6A1 haploinsufficiency disorder, and TSHA-104 for Surfeit locus 1 deficiency. Taysha Gene Therapies aims to translate innovative treatments from research to clinical practice efficiently, leveraging a strategic partnership with The University of Texas Southwestern Medical Center to enhance its development and commercialization capabilities. The company's mission is to create curative medicines that target both rare and prevalent CNS conditions, thereby addressing severe and life-threatening diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.